Molecular cancer therapy: can our expectation be MET?

@article{Migliore2008MolecularCT,
  title={Molecular cancer therapy: can our expectation be MET?},
  author={Cristina Migliore and Silvia Giordano},
  journal={European journal of cancer},
  year={2008},
  volume={44 5},
  pages={641-51}
}
Altered regulation of tyrosine kinase receptors (RTKs) is frequent in solid tumours and it is often associated with the acquisition of an aggressive phenotype. Thus, therapies targeting these receptors have been proposed as molecular approaches to treat human cancers. The MET proto-oncogene, encoding the tyrosine kinase receptor for hepatocyte growth factor (HGF), controls genetic programmes leading to cell growth, invasion and protection from apoptosis. Germ-line mutations of MET in patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 55 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 90 references

A Phase 2 study of the dual MET / VEGFR 2 inhibitor XL 880 in patients ( pts ) with papillary renal carcinoma ( PRC )

RW Ross, R Srinivasan, U Vaishampayan
AACR – NCI – EORTC – international conference – molecular targets and cancer therapeutics • 2007

A Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor administered daily to patients (pts) with advanced malignacies

GI Shapiro, E Heath, L. Malburg
In: AACR–NCI–EORTC – International conference – molecular targets and cancer therapeutics, • 2007
View 1 Excerpt

A phase 1 dose escalation study and signs of anti-metastatic activity of ARQ197, a selective c-Met inhibitor

L Rosen, N Senzer, J. Nemunaitis
In: AACR–NCI–EORTC – international conference – molecular targets and cancer therapeutics, • 2007
View 1 Excerpt

A phase 1 doseescalation study of the safety and pharmacokinetics ( PK ) of XL 184 , a VEGFR and MET kinase inhibitor , administered orally to patients ( pts ) with advanced malignancies

R Salgia, D Hong, SI Sherman, NG Chann
AACR – NCI – EORTC – international conference – molecular targets and cancer therapeutics • 2007

ARQ197, a small molecule inhibitor of c-Met, prevents bone metastases in humanized mouse model of breast cancer

KM Anderson, CJ Li, J. Moreau
molecular targets and cancer therapeutics, • 2007
View 1 Excerpt

Similar Papers

Loading similar papers…